[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zentrum fur Humangenetik Tuebingen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":4,"overallStatus":20,"whyStopped":4,"lastUpdateSubmitDate":21,"lastUpdatePostDateStruct":22,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":25,"locationsCount":5},"100466636",false,"NCT05356312","Glioblastoma and Individualized Therapies","Retrospective Analysis of Glioblastoma Patients With Immune Therapies","Inclusion Criteria:\n\n* malignant glioma, IDH WT\n\nExclusion Criteria:\n\n* na","ALL","EXPANDED_ACCESS","The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio \u002F chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.",[19],"Glioma, Malignant","AVAILABLE","2024-02-29",{"date":23,"type":24},"2024-03-01","ACTUAL",{"name":26,"class":27},"Zentrum fur Humangenetik Tuebingen","OTHER",""]